A Phase 2 Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Go Back to All Clinical Trials

A Phase 2 Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Brief description of study

This is a phase 2, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of ALXN2050, an oral complement FD inhibitor, in adult participants with proliferative lupus nephritis (LN) or Immunoglobulin A Nephropathy (IgAN).

Clinical Study Identifier: s22-00142

ClinicalTrials.gov Identifier: NCT05097989

Principal Investigator: Howard Belmont.

Other Investigator: Janine M. Sullivan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies